WPG Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$166K Buy
2,664
+38
+1% +$2.4K 0.09% 122
2026
Q2
$151K Buy
2,626
+787
+43% +$45.2K 0.09% 134
2026
Q1
$112K Buy
1,839
+71
+4% +$4.14K 0.08% 134
2025
Q4
$95.4K Buy
1,768
+469
+36% +$22.6K 0.07% 171
2025
Q3
$58.6K Sell
1,299
-428
-25% -$20K 0.05% 256
2025
Q2
$79.9K Buy
1,727
+624
+57% +$30.6K 0.07% 194
2025
Q1
$67.3K Buy
1,103
+328
+42% +$19.1K 0.06% 214
2024
Q4
$43.8K Buy
+775
New +$43.3K 0.04% 313

Other funds holding BMY

WPG Advisers's BMY Position: Q3 2026 in Review

WPG Advisers increased its Bristol-Myers Squibb (BMY) stake by 1.4% in Q3 2026, buying an estimated $2.4K and bringing the position to 2,664 shares worth $166K. The position accounts for 0.09% of the portfolio, ranked #122.

WPG Advisers first reported a position in BMY in Q4 2024 and has held it in 8 quarters since. 1,436 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • WPG Advisers held 2,664 shares of Bristol-Myers Squibb worth $166K as of Q3 2026.
  • WPG Advisers bought 38 Bristol-Myers Squibb shares in Q3 2026, an estimated $2.4K.
  • Bristol-Myers Squibb made up 0.09% of WPG Advisers's portfolio in Q3 2026, its #122 holding.
  • WPG Advisers first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 8 quarters since.
  • 1,436 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on WPG Advisers's 13F filing for Q3 2026, filed 27 Oct 2026.